IXHL
$3.31
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia.
Recent News
Incannex Healthcare Inc. (IXHL) Implements 1-for-30 Reverse Split Effective February 26
Incannex Healthcare Inc. (NASDAQ:IXHL) is among the 11 Best Pot Stocks to Buy According to Hedge Funds. On February 25, Incannex Healthcare Inc. (NASDAQ:IXHL) announced that its board of directors approved a 1-for-30 reverse stock split of the company’s common stock. The reverse split had previously been approved by stockholders at a special meeting held […]
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Tilray Rebranded Italian Medical Cannabis Arm as Tilray Medical Italia Aurora Cannabis Won EU-wide Protection for its Farm Gas and Sourdough Cannabis Varieties Simply Solventless Sharpened Growth Strategy with Uncommon Cannabis Acquisition and Humble Retrofit Progress Key Takeaways; Psychedelic Sector Definium Therapeutics Launched ‘Rerouting Minds’ Campaign to Spotlight the Science Behind […]
What Makes Incannex Healthcare Inc. (IXHL) a New Buy Stock
Incannex Healthcare Inc. (IXHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 1% and the Hea
Wall Street Set to Open Higher Friday as Investors Await Powell's Speech at Jackson Hole
US stocks are set to open higher in Friday's trading session as investors look ahead to Federal Rese